ClinicalTrials.gg
RecruitingNCT05234723ReCySOHTUpdated Jun 15, 2026

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

An observational study in Cytomegalovirus Infections, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 23 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cytomegalovirus Infections with a site in Italy — 5 open to participants now, 6 under way, 1 of them phase 3. Cytomegalovirus Infections · Italy.

Started
2023
with 1 other
Observational
4 of 18
3 open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Among the 18 studies in Cytomegalovirus Infections with a site in Italy, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 13th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

5 of the 18 studies in Cytomegalovirus Infections with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cytomegalovirus Infections with a site in Italy, or all of them as a file.
02

Study summary

The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

Read the detailed description

Cytomegalovirus (CMV) is an important cause of morbidity and mortality in solid organ transplant (SOT) patients and hematopoietic stem cell transplant (HSCT) patients. Ganciclovir (GCV) is the first line therapy for treatment and prevention of CMV infection in SOT and HSCT recipients, with established efficacy and relatively safe profile.

Ganciclovir-resistant or refractory (GCV-RR) CMV is an uncommon but frightening clinical problem due to limited, toxic and less effective therapeutic alternative drugs. Indeed, some studies indicate that GCV-RR is associated with significant additional attributable morbidity and mortality in SOT and HSCT recipients compared with ganciclovir susceptible (GCV-S) CMV disease.

Few data are available about the incidence of GCV-RR-CMV in SOT and HSCT patients showing a range from 0% to 3% . The serological mismatch group and the type of SOT have been reported as the main factors influencing such range. Indeed, in one of the largest experience now available in SOT, the incidence of GCV-resistant (GCV-RT) CMV infection accounted up to 12% in a cohort of lung transplant recipients. Among HSCT patients, haploidentical, allogeneic unrelated, and cord blood HSCT have been associated with increased risk of GCV-RR CMV infection. Among risk factors for GCV-RR, high-risk D/R subset (R- in SOT and R+ in HSCT), high viral loads, inadequate drug delivery, increased durations of antiviral drug exposure and the use of more potent immunosuppressive regimens have been reported. However, these reports come from small, monocentric experiences with a limited number of cases, providing a fragmentary picture of the overall burden and epidemiological characteristics of GCV-RR in transplant patients. Information of the epidemiological background of GCV-RR after transplantation could be helpful in improving preventive management and reducing the emergence of GCV-RT episodes. Indeed, studies investigating viral genetic alterations showed that mutations conferring ganciclovir resistance are not present at baseline but emerge and become amplified over time, especially in the presence of an incompletely suppressive drug exposure. The GCV-RT is due to mutations in UL97 and UL54 genes. UL97 mutations confer various degrees of phenotypic resistance to ganciclovir. Mutations in UL54 determine higher-level resistance to ganciclovir and usually appear as a second step after mutations in UL97.

The investigators carry-out a multicenter retrospective observational study to define incidence of GCV-RR CMV-infection in SOT and HSCT patients and to identify the risk factors for its development in SOT and HSCT recipients. Data from this study could be useful to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

03

Conditions studied

  • Cytomegalovirus Infections

Keywords

  • Ganciclovir-resistant CMV
  • Cytomegalovirus
  • Solid Organ Transplant
  • Ganciclovir
  • Ganciclovir-refractory CMV
  • Hematopoietic Stem Cell Transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC during the study period will be screened for inclusion according to inclusion and exclusion criteria. Eligible patients will be classified as cases or controls according to the following definitions:

  • Case: SOT or HSCT recipients with genotypically confirmed GCV-RR CMV-event;
  • Control: SOT or HSCT recipients with "presumed" GCV-S CMV-event on the basis of good microbiological and clinical response to standard GCV/VGC treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult (≥ 18 years) patients who underwent SOT or developing CMV-infection treated with GC/VGC
  • Ability to understand the purpose of the study and provide signed and dated

Exclusion criteria

Exclusion Criteria:

  • Lack of clinical and/or laboratory data regarding the type of CMV event
  • Lack of the serological mismatch at transplantation
  • Lack of the type of SOT or
  • Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Solid Organ Transplant and Hematopoietic Stem Cell Transplant patients

    Solid Organ Transplant (SOT) and Hematopoietic Stem Cell Transplant (HSCT) patients with Ganciclovir Resistant or Refractory Cytomegalovirus infection

06

What researchers measure

Primary outcomes

  1. To define incidence of GCV-RR CMV-infection in SOT and HSCT patients

    To define incidence of GCV-RR CMV-infection in SOT and HSCT patients

    Time frame: Through study completion, an average of 1 year

  2. To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patients

    To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patients

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. To compare type of CMV episode between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare type of CMV episode: infection or disease (the last cathegorized as CMV syndrome or Tissue invasion) between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  2. To compare virological cure between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare virological cure at 30, 60 and 90 days after CMV infection diagnosis and relapse of CMV infection between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  3. To compare clinical cure between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare clinical cure at 30, 60 and 90 days after CMV infection diagnosis between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  4. To compare graft outcome between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare graft failure rate and the need of re-transplant between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  5. To compare the need of ICU and hospital stay between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare total length of ICU and hospital stay between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  6. To compare the need of readmission in ICU and/or hospital between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare the need of readmission in ICU and/or hospital between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  7. To compare all-cause mortality between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    To compare all-cause mortality during infection episode and follow-up (30, 60, 90 days after the first CMV infection diagnosis) between SOT and HSCT patients with GCV-RR versus GCV-S CMV-infection

    Time frame: Through study completion, an average of 1 year

  8. To describe the therapeutic management of GCV-RR CMV-infection

    To describe the therapeutic management of GCV-RR CMV-infection including the use of CMV-specific T-cell assay

    Time frame: Through study completion, an average of 1 year

07

Study locations

7 of 23 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Feb 2027, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2022
First posted
Feb 10, 2022
StartActual
Jun 19, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05234723
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Jun 19, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Renato Pascale, MD
Contact
renato.pascale@aosp.bo.it
+390512144350
Maddalena Giannella, MD, PhD
Contact
maddalena.giannella@unibo.it
+390512143199
Renato Pascale, MD
principal investigator · IRCCS AOUBO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion